Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion

Cytokine

Volumn 59, Issue 1, 2012, Pages 145-155

  Wang, Yue ^a,b   Xu, Rui Cheng ^a   Zhang, Xiao Lei ^b   Niu, Xiu Long ^b   Qu, Ye ^b   Li, Ling Zhi ^a   Meng, Xiang Yan ^b  

^a Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Interleukin 8(IL 8); Malignant behaviors; Ovarian cancer (OVCA); PI3K Akt and Raf MEK ERK signaling

Indexed keywords

CYCLIN B1; CYCLIN D1; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ARTICLE; CANCER CELL; CELL ADHESION; CELL CYCLE REGULATION; CELL INVASION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN A2780; CELL STRAIN SKOV 3; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN B1; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHENOTYPE; RNA, MESSENGER; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861709168     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.04.013     Document Type: Article

References (56)

1. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998, 90:1774-1786.
2. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502-516.
3. Roebuck K.A. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res 1999, 19:429-438.
4. Waugh D.J.J., Wilson C. The interleukin-8 Pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
5. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 12:375-391.
6. Tanaka T., Bai Z., Srinoulprasert Y., Yang B., Hayasaka H., Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005, 96:317-322.
7. Ivarsson K., Runesson E., Sundfeldt K., Haeger M., Hedin L., Janson P.O., et al. The chemotactic cytokine interleukin-8 - a cyst fluid marker for malignant epithelial ovarian cancer?. Gynecol Oncol 1998, 71:420-423.
8. Ivarsson K., Ekerydh A., Fyhr I.M., Janson P.O., Brännström M. Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstet Gynecol Scand 2000, 79:777-784.
9. Penson R.T., Kronish K., Duan Z., Feller A.J., Stark P., Cook S.E., et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000, 10:33-41.
10. Fasciani A., D'Ambrogio G., Bocci G., Luisi S., Artini P.G., Genazzani A.R. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 2001, 75:1218-1221.
11. Herrera C.A., Xu L., Bucana C.D., Silvael V.G., Hess K.R., Gershenson D.M., et al. Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol 2002, 20:5-13.
12. Kassim S.K., El-Salahy E.M., Fayed S.T., Helal S.A., Helal T., Azzam Eel-D., et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004, 37:363-369.
13. Lokshin A.E., Winans M., Landsittel D., Marrangoni A.M., Velikokhatnaya L., Modugno F., et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006, 102:244-251.
14. 2nd R.L., Webb T.J., Zoso A., Rogers O., Diaz-Montes T.P., Bristow R.E., et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009, 29:2875-2884.
15. Nowak M., Glowacka E., Szpakowski M., Szyllo K., Malinowski A., Kulig A., et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010, 31:375-383.
16. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008, 100:359-372.
17. Uslu R., Sanli U.A., Dikmen Y., Karabulut B., Ozsaran A., Sezgin C., et al. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. Int J Gynecol Cancer 2005, 15:240-245.
18. Wang Y., Qu Y., Niu X.L., Sun W.J., Zhang X.L., Li L.Z. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011, 56:365-375.
19. Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M., et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 2008, 6:917-928.
20. Wang Y., Niu X., Qu Y., Wu J., Zhu Y., Sun W., et al. Autocrine production of Interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123.
21. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994, 218:325-329.
22. Wang Y., Yang J., Gao Y., Dong L.J., Liu S., Yao Z. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther 2007, 6:864-871.
23. Yang J., Wang Y., Gao Y., Shao J., Zhang X.J., Yao Z. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine 2009, 46:382-391.
24. Singh S., Sadanandam A., Singh R.K. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007, 26:453-467.
25. Inoue K., Slaton J.W., Eve B.Y., Kim S.J., Perrotte P., Balbay M.D., et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000, 6:2104-2119.
26. Kim S.J., Uehara H., Karashima T., Mccarty M., Shih N., Fidler I.J. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001, 3:33-42.
27. Xu L., Fidler I.J. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res 2000, 12:97-106.
28. Huang S., Robinson J.B., Deguzman A., Bucana C.D., Fidler I.J. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000, 60:5334-5339.
29. Alper O., DeSantis M.L., Stromberg K., Hacker N.F., Cho-Chung Y.S., Salomon D.S. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer 2000, 88:566-574.
30. Murdoch C., Monk P.N., Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999, 11:704-712.
31. Takamori H., Oades Z.G., Hoch O.C., Burger M., Schraufstatter I.U. Autocrine growth effect of IL-8 and GRO on a human pancreatic cancer cell line, Capan-1. Pancreas 2000, 21:52-56.
32. Brew R., Erikson J.S., West D.C., Kinsella A.R., Slavin J., Christmas S.E. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 2000, 12:78-85.
33. Kamohara H., Takahashi M., Ishiko T., Ogawa M., Baba H. Induction of interleukin-8 (CXCL-8) by tumor necrosis facto and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol 2007, 31:627-632.
34. Lang K., Niggemann B., Zanker K.S., Entschladen F. Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer 2002, 99:673-680.
35. Yao C., Lin Y., Chua M.S., Ye C.S., Bi J., Li W., et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 2007, 121:1949-1957.
36. Araki S., Omori Y., Lyn D., Singh R.K., Meinbach D.M., Sandman Y., et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007, 67:6854-6862.
37. Singh R.K., Lokeshwar B.L. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 2009, 8:57-71.
38. Maxwell P.J., Gallagher R., Seaton A., Wilson C., Scullin P., Pettigrew J., et al. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007, 26:7333-7345.
39. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002, 161:125-134.
40. Shi Q., Abbruzzese J.L., Huang S., Fidler I.J., Xiong Q., Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999, 5:3711-3721.
41. Inoue K., Slaton J.W., Kim S.J., Perrotte P., Eve B.Y., Bar-Eli M., et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000, 60:2290-2299.
42. Karashima T., Sweeney P., Kamat A., Huang S., Kim S.J., Bar-Eli M., et al. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003, 9:2786-2797.
43. Mian B.M., Dinney C.P., Bermejo C.E., Sweeney P., Tellez C., Yang X.D., et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 2003, 9:3167-3175.
44. Lee L.F., Hellendall R.P., Wang Y., Haskill J.S., Mukaida N., Matsushima K., et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 2000, 164:2769-2775.
45. MacManus C.F., Pettigrew J., Seaton A., Wilson C., Maxwell P.J., Berlingeri S., et al. Interleukin-8 signaling promotes translational of regulation cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 2007, 5:737-748.
46. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009, 284:6038-6042.
47. Inou K., Wood G.C., Slaton J.W., Karashima T., Sweeney P., Dinney C.P. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukine-8. Oncol Rep 2001, 8:955-964.
48. Bar J.K., Grelewski P., Popiela A., Noga L., Rabczynski J. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol 2004, 95:23-31.
49. Luca M., Huang S., Gershenwald J.E., Singh R.K., Reich R., Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997, 151:1105-1113.
50. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
51. Cheng G.Z., Park S., Shu S., He L., Kong W., Zhang W., et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 2008, 8:2-6.
52. Venkatakrishnan G., Salgia R., Groopman J.E. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 2000, 275:6868-6875.
53. Luppi F., Longo A.M., de Boer W.I., Rabe K.F., Hiemstra P.S. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 2007, 56:25-33.
54. Glynn P.C., Henney E., Hall I.P. The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-a-mediated inhibition of spontaneous neutrophil apoptosis. Pulm Pharmacol Ther 2002, 15:103-110.
55. Meng Q., Xia C., Fang J., Rojanasakul Y., Jiang B.H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006, 18:2262-2271.
56. Steinmetz R., Wagoner H.A., Zeng P., Hammond J.R., Hannon T.S., Meyers J.L., et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 2004, 18:2570-2582.